NASDAQ: IMGN
ImmunoGen Inc Stock

$5.40-0.05 (-0.92%)
Updated Jan 25, 2022
IMGN Price
$5.40
Fair Value Price
$6.60
Market Cap
$1.09B
52 Week Low
$4.73
52 Week High
$10.88
P/E
-17.42x
P/B
14.19x
P/S
9.1x
PEG
N/A
Dividend Yield
N/A
Revenue
$127.66M
Earnings
-$70.74M
Gross Margin
100%
Operating Margin
-55.36%
Profit Margin
-55.4%
Debt to Equity
2.85
Operating Cash Flow
-$115M
Beta
1.39
Next Earnings
Feb 10, 2022
Ex-Dividend
N/A
Next Dividend
N/A

IMGN Overview

Zen Score

High
Medium
Low
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMGN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMGN ($5.40) is undervalued by 18.18% relative to our estimate of its Fair Value price of $6.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
IMGN is poor value based on its book value relative to its share price (14.19x), compared to the US Biotechnology industry average (4.53x)
Valuation
IMGN's cash and short-term investments... subscribe to Premium to read more.
Financials
There are 18 more IMGN due diligence checks available for Premium users.

IMGN News

Valuation

IMGN fair value

Fair Value of IMGN stock based on Discounted Cash Flow (DCF)
Price
$5.40
Fair Value
$6.60
Undervalued by
18.18%
IMGN ($5.40) is undervalued by... subscribe to Premium to read more.
Valuation

IMGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-17.42x
Industry
21x
Market
33.66x

IMGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
14.19x
Industry
4.53x
IMGN is poor value based... subscribe to Premium to read more.
Valuation

IMGN's financial health

Profit margin

Revenue
$9.2M
Net Income
-$37.3M
Profit Margin
-405.4%
IMGN's cash and short-term investments... subscribe to Premium to read more.
Financials
IMGN's profit margin has increased... subscribe to Premium to read more.
Financials

Assets to liabilities

Assets
$296.8M
Liabilities
$219.7M
Debt to equity
2.85
IMGN's short-term assets ($270.89M) exceed... subscribe to Premium to read more.
Financials
IMGN's short-term assets ($270.89M) exceed... subscribe to Premium to read more.
Financials
IMGN's debt relative to shareholder... subscribe to Premium to read more.
Financials
IMGN's debt to equity ratio... subscribe to Premium to read more.
Financials

Cash flow

Operating
-$35.0M
Investing
-$125.0k
Financing
$41.4M
IMGN's cash and short-term investments... subscribe to Premium to read more.
Financials

ImmunoGen Stock FAQ

What is ImmunoGen's quote symbol?

(NASDAQ: IMGN) ImmunoGen trades on the NASDAQ under the ticker symbol IMGN. ImmunoGen stock quotes can also be displayed as NASDAQ: IMGN.

What is the 52 week high and low for ImmunoGen (NASDAQ: IMGN)?

(NASDAQ: IMGN) ImmunoGen's 52-week high was $10.88, and its 52-week low was $4.73. It is currently -50.37% from its 52-week high and 14.29% from its 52-week low.

How much is ImmunoGen stock worth today?

(NASDAQ: IMGN) ImmunoGen currently has 202,619,488 outstanding shares. With ImmunoGen stock trading at $5.40 per share, the total value of ImmunoGen stock (market capitalization) is $1.09B.

ImmunoGen stock was originally listed at a price of $0.84 in Dec 31, 1997. If you had invested in ImmunoGen stock at $0.84, your return over the last 24 years would have been 539.81%, for an annualized return of 8.04% (not including any dividends or dividend reinvestments).

How much is ImmunoGen's stock price per share?

(NASDAQ: IMGN) ImmunoGen stock price per share is $5.40 today (as of Jan 25, 2022).

What is ImmunoGen's Market Cap?

(NASDAQ: IMGN) ImmunoGen's market cap is $1.09B, as of Jan 26, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

ImmunoGen's market cap is calculated by multiplying IMGN's current stock price of $5.40 by IMGN's total outstanding shares of 202,619,488.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.